ECSP14001929A - Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y proceso para su preparación. - Google Patents

Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y proceso para su preparación.

Info

Publication number
ECSP14001929A
ECSP14001929A ECIEPI20141929A ECPI201401929A ECSP14001929A EC SP14001929 A ECSP14001929 A EC SP14001929A EC IEPI20141929 A ECIEPI20141929 A EC IEPI20141929A EC PI201401929 A ECPI201401929 A EC PI201401929A EC SP14001929 A ECSP14001929 A EC SP14001929A
Authority
EC
Ecuador
Prior art keywords
medicines
contain
preparation
heterocyclic compounds
salts
Prior art date
Application number
ECIEPI20141929A
Other languages
English (en)
Spanish (es)
Inventor
Joerg Kley
Dieter Hamprecht
Sara Frattini
Armin Heckel
Original Assignee
Sanofi Aventis Deutschiand Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschiand Gmbh filed Critical Sanofi Aventis Deutschiand Gmbh
Publication of ECSP14001929A publication Critical patent/ECSP14001929A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
ECIEPI20141929A 2011-11-02 2014-05-26 Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y proceso para su preparación. ECSP14001929A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11187553 2011-11-02

Publications (1)

Publication Number Publication Date
ECSP14001929A true ECSP14001929A (es) 2015-11-30

Family

ID=47073464

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20141929A ECSP14001929A (es) 2011-11-02 2014-05-26 Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y proceso para su preparación.

Country Status (34)

Country Link
US (4) US8759349B2 (enExample)
EP (1) EP2773633B1 (enExample)
JP (1) JP6091513B2 (enExample)
KR (1) KR102006612B1 (enExample)
CN (2) CN106279110B (enExample)
AP (1) AP2014007670A0 (enExample)
AU (1) AU2012331274B2 (enExample)
BR (1) BR112014010583A2 (enExample)
CA (1) CA2854217C (enExample)
CL (1) CL2014001047A1 (enExample)
CO (1) CO6940429A2 (enExample)
CY (1) CY1120974T1 (enExample)
DK (1) DK2773633T3 (enExample)
EA (1) EA025158B9 (enExample)
EC (1) ECSP14001929A (enExample)
ES (1) ES2645744T3 (enExample)
GE (2) GEP20186880B (enExample)
HR (1) HRP20171614T1 (enExample)
HU (1) HUE034929T2 (enExample)
IL (1) IL232035A (enExample)
LT (1) LT2773633T (enExample)
ME (1) ME02905B (enExample)
MX (1) MX348522B (enExample)
NO (1) NO2773633T3 (enExample)
PE (1) PE20141607A1 (enExample)
PH (1) PH12014500970B1 (enExample)
PL (1) PL2773633T3 (enExample)
PT (1) PT2773633T (enExample)
RS (1) RS56498B1 (enExample)
SG (1) SG11201401907TA (enExample)
SI (1) SI2773633T1 (enExample)
TN (1) TN2014000180A1 (enExample)
UA (1) UA115868C2 (enExample)
WO (1) WO2013064450A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
NO2773633T3 (enExample) * 2011-11-02 2017-12-30
CA2915633A1 (en) * 2013-07-02 2015-01-08 The California Institute For Biomedical Research Compounds for treatment of cystic fibrosis
WO2015003958A1 (en) * 2013-07-08 2015-01-15 Boehringer Ingelheim International Gmbh Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
SG11201703284XA (en) 2014-10-24 2017-06-29 Ono Pharmaceutical Co Kcnq2-5 channel activator
CN107405505A (zh) * 2015-01-07 2017-11-28 加州生物医学研究所 用于治疗囊性纤维化的化合物
GB201610854D0 (en) 2016-06-21 2016-08-03 Entpr Therapeutics Ltd Compounds
GB201619694D0 (en) 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
GB201717051D0 (en) 2017-10-17 2017-11-29 Enterprise Therapeutics Ltd Compounds
GB201808093D0 (en) 2018-05-18 2018-07-04 Enterprise Therapeutics Ltd Compounds
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
CN112107580A (zh) * 2020-09-29 2020-12-22 北京鑫开元医药科技有限公司 一种脾酪氨酸激酶抑制剂的制剂组合物及其制备方法
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2024243025A1 (en) * 2023-05-19 2024-11-28 Ikena Oncology, Inc. Naphthyl-substituted pyrido[4,3-d]pyrimidines and related compounds and their use in treating medical conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6812003A (enExample) 1967-09-07 1969-03-11
US3953476A (en) 1971-12-27 1976-04-27 Merck & Co., Inc. 3-Amino-5-sulfonylbenzoic acids
ATE390414T1 (de) 1999-07-19 2008-04-15 Univ North Carolina Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten
JP2003520042A (ja) 2000-01-24 2003-07-02 アイシス・ファーマシューティカルス・インコーポレーテッド 誘導性一酸化窒素シンターゼ発現のアンチセンスモジュレーション
CA2575670A1 (en) 2004-08-18 2006-03-02 Michael R. Johnson Aliphatic amide & ester pyrazinoylguanidine sodium channel blockers
GB0526244D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2484308A1 (en) * 2006-07-24 2012-08-08 International Stem Cell Corporation Synthetic cornea from retinal stem cells
EP2332933A1 (en) * 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
BRPI0820669A2 (pt) 2007-12-10 2020-08-04 Novartis Ag compostos orgânicos
MX2010012441A (es) * 2008-05-13 2010-12-06 Novartis Ag Derivados de acido 3,5-diamino-6-cloro-pirazin-2-carboxilico y su uso como bloqueadores del canal de sodio epitelial para el tratamiento de enfermedades de las vias respiratorias.
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US9050339B2 (en) 2010-09-17 2015-06-09 Novartis Ag Pyrazine derivatives as ENaC blockers
SI2723176T1 (sl) 2011-06-27 2017-09-29 Parion Sciences, Inc. Kemijsko in metabolno stabilni dipeptid, ki ima močno aktivnost blokiranja natrijevega kanala
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
AU2012331275A1 (en) 2011-11-02 2014-04-03 Boehringer Ingelheim International Gmbh Novel process for the preparation of acylguanidines and acylthioureas
NO2773633T3 (enExample) * 2011-11-02 2017-12-30

Also Published As

Publication number Publication date
AU2012331274A1 (en) 2014-04-03
EP2773633B1 (en) 2017-08-02
SG11201401907TA (en) 2014-05-29
AU2012331274B2 (en) 2017-06-08
CN106279110A (zh) 2017-01-04
RS56498B1 (sr) 2018-01-31
SI2773633T1 (sl) 2017-11-30
HUE034929T2 (en) 2018-03-28
CL2014001047A1 (es) 2014-11-07
CN106279110B (zh) 2019-12-10
CA2854217C (en) 2019-12-31
CO6940429A2 (es) 2014-05-09
NO2773633T3 (enExample) 2017-12-30
US20140228374A1 (en) 2014-08-14
HK1196819A1 (zh) 2014-12-24
GEAP201813485A (en) 2018-04-10
NZ622469A (en) 2016-08-26
PL2773633T3 (pl) 2018-01-31
GEP20186880B (en) 2018-07-25
TN2014000180A1 (en) 2015-09-30
EP2773633A1 (en) 2014-09-10
US20180194747A1 (en) 2018-07-12
US8759349B2 (en) 2014-06-24
JP6091513B2 (ja) 2017-03-08
PE20141607A1 (es) 2014-11-23
IL232035A (en) 2017-05-29
JP2014534222A (ja) 2014-12-18
CN104024244B (zh) 2016-09-14
MX2014005166A (es) 2014-05-28
MX348522B (es) 2017-06-16
EA201400521A1 (ru) 2014-09-30
KR102006612B1 (ko) 2019-08-02
CN104024244A (zh) 2014-09-03
HRP20171614T1 (hr) 2017-12-01
EA025158B1 (ru) 2016-11-30
LT2773633T (lt) 2017-11-10
DK2773633T3 (da) 2017-11-13
BR112014010583A2 (pt) 2020-04-22
PH12014500970A1 (en) 2014-06-09
KR20140085498A (ko) 2014-07-07
CA2854217A1 (en) 2013-05-10
ME02905B (me) 2018-10-20
PT2773633T (pt) 2017-11-14
IL232035A0 (en) 2014-05-28
UA115868C2 (uk) 2018-01-10
US20130109697A1 (en) 2013-05-02
CY1120974T1 (el) 2019-12-11
PH12014500970B1 (en) 2017-10-06
ES2645744T3 (es) 2017-12-07
AP2014007670A0 (en) 2014-05-31
WO2013064450A1 (en) 2013-05-10
US9920035B2 (en) 2018-03-20
US20150336933A1 (en) 2015-11-26
EA025158B9 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
UA115868C2 (uk) Гетероциклічні сполуки, лікарські засоби, які містять зазначені сполуки, їх застосування і способи їх одержання
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
ECSP099750A (es) Imidazoquinolinas con propiedades inmunomoduladoras
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
MX2020012520A (es) Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia.
NI201400108A (es) Compuestos de heterociclilo
UY36112A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
UY32848A (es) Compuestos heterocíclicos de oxima
CR20180316A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CU20110088A7 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
CO6351777A2 (es) Compuestos de tetraciclina sustituidod con fluor en c7
CO2019012571A2 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
UY32247A (es) Nuevos compuestos de aminociclohexilo, composiciones farmacéuticas de los mismos y aplicaciones
TR201310724A2 (tr) Linagliptinin farmasotik formulasyonları.
CL2012001641A1 (es) Compuestos derivados de piperazina; composición farmacéutica; que comprende a uno de los compuestos y uso de los compuestos en la preparación de medicamentos para el tratamiento y/o prevención de infecciones por protozoos, en forma particular para el tratamiento y/o prevención de la malaria.
MX2019007950A (es) Inhibidores tripeptidicos de la epoxicetona proteasa.